Serological Responses To Anal HPV Infection: Characterising The Natural History Of Anal HPV
Funder
National Health and Medical Research Council
Funding Amount
$220,506.00
Summary
Human papillomavirus (HPV) causes 90% of anal cancer. Anal cancer rates are 20-100 times higher in gay men than other men. The natural history of anal HPV infection and progression to cancer is not completely understood. This study measuring antibodies to HPV will be part of the ongoing Study of the Prevention of Anal Cancer. We aim to show 1) if infection provides any immunity, which will inform HPV vaccination of older gay men and 2) whether antibodies could be used as a marker of cancer risk.
A Vulvar Cancer Cluster Caused By Genetic Susceptibility: Investigating The Genetic Mechanism.
Funder
National Health and Medical Research Council
Funding Amount
$1,154,342.00
Summary
Cancer of the vulva is 70 times more common in young Aboriginal women in Arnhem Land than in other women. Human Papillomavirus (HPV), which also causes cervical cancer, is the usual cause of this cancer; initial investigations have found that HPV is present in these cancers but is not the reason for the excessive incidence. This study will investigate inherited risk factors contributing to the development of this disease in this population.
Aurora A As A Novel Therapeutic Target For HPV-driven Cancers.
Funder
National Health and Medical Research Council
Funding Amount
$762,328.00
Summary
Cervical cancer is caused by a virus and current treatments have not improved for many years. We have performed a screen and identified new drug targets and here we will examine one of these using a drug that has perviously been developed for other cancers. Our preliminary data shows cervical cancer is highly sensitive to this drug and there are few side-effects. We will examine how it works and if it results in permanent protection from new cancers.
HPV And Oropharyngeal Cancer In Indigenous Australians
Funder
National Health and Medical Research Council
Funding Amount
$1,547,109.00
Summary
Oropharyngeal cancers are frequently excluded cancers affecting Aboriginal and Torres Strait Islander Australians. HPV is a significant risk factor for oropharyngeal cancer. HPV vaccination is effective against HPV, with some promise that current vaccines may prevent oral infections; potentially reducing the risk of oropharyngeal cancer. The project will have important outcomes to improve risk of HPV infection and oropharyngeal cancers among Aboriginal and Torres Strait Islander Australians.
Randomised Controlled Trial Of HPV Self-sampling For Improving Participation In Cervical Screening: The IPAP Trial
Funder
National Health and Medical Research Council
Funding Amount
$534,461.00
Summary
Effectiveness of cervical cancer screening relies on maximising participation. Unlike a Pap test, an HPV test may be self-collected and this may overcome some of the barriers to Pap testing. Overseas trials have found higher uptake for HPV self-sampling (between 3-30%) compared with Pap test reminder letters. We will conduct the first randomised trial in Australia comparing home-based HPV self-sampling with a reminder letter, to evaluate whether this improves participation and followup.
Effectiveness And Cost-Effectiveness Of HPV Vaccination And HPV-Based Cervical Cancer Screening Strategies In China
Funder
National Health and Medical Research Council
Funding Amount
$420,692.00
Summary
In the absence of preventative initiatives, up to 187,000 women will develop cervical cancer in China every year. However, the disease is preventable using human papillomavirus (HPV) vaccination and primary HPV screening. Building on previous work, we will evaluate the most effective and cost-effective options for cervical cancer prevention, in order to provide an comprehensive evidence base for China’s health decision-makers.
Point-of-care HPV-DNA Testing For Cervical Cancer Screening In High-burden, Low-resource Settings
Funder
National Health and Medical Research Council
Funding Amount
$891,184.00
Summary
We will undertake the first field evaluation of a novel, newly-available, easy to use, and highly accurate point-of-care (POC) test for high-risk human papillomavirus (hrHPV) infection that will allow trained health staff to identify women at increased risk of cervical cancer and to provide same-day cervical cryotherapy for pre-cancer lesions identified on clinical examination.
Evaluation Of Outcomes And Cost-effectiveness Of Implementing Next Generation Human Papillomavirus (HPV) Vaccination And Associated Primary HPV-based Cervical Cancer Screening Strategies In Australia
Funder
National Health and Medical Research Council
Funding Amount
$697,071.00
Summary
This project involves using simulation modelling to predict the effect of the next generation human papillomavirus (HPV) vaccine, which will protect against infection with more strains of HPV. The investigators will use large datasets garnered from around the world to inform the assessment of the cost-effectiveness of this new vaccine in Australia and other key countries, and also to assess whether cervical screening will need to change in the future to account for the introduction of the new va ....This project involves using simulation modelling to predict the effect of the next generation human papillomavirus (HPV) vaccine, which will protect against infection with more strains of HPV. The investigators will use large datasets garnered from around the world to inform the assessment of the cost-effectiveness of this new vaccine in Australia and other key countries, and also to assess whether cervical screening will need to change in the future to account for the introduction of the new vaccine.Read moreRead less
Cancer is constantly being suppressed in our bodies by a process that stops damaged cells from growing: 'senescence'. The mechanism that translates the damage stimuli into this state of permanent cell arrest is only partially known. We have identified a protein that appears to drive this restraint. The possibility of manipulating this process to prevent and cure cancer makes it in important target to study.
Randomised Controlled Evaluation Of A Complex Intervention To Promote Uptake Of School-based HPV Vaccination
Funder
National Health and Medical Research Council
Funding Amount
$750,911.00
Summary
Adolescents have little understanding and high levels of fear about HPV vaccination in the Australian school program. We plan to evaluate a multi-strategy intervention (incorporating an adolescent education intervention, a parental decision aid, and procedural facilitators) to promote uptake and informed participation in the school-based HPV vaccination program. The intervention will promote understanding, reduce fear, and have minimum impact on school and teacher resources.